Diquas (diquafosol) / Merck (MSD), Santen - LARVOL DELTA

Effectiveness of Dry Eye Treatment With Diquafosol Sodium 3% After Phaco Surgery (clinicaltrials.gov) - P=N/A | N=60 | Completed | Sponsor: Le Xuan Cung

New trial • Dry Eye Disease • Ophthalmology

The Impact of 3% Diquafosol Ophthalmic Solution on Tear Film and Corneal Nerve Density in Patients with Diabetes and Dry Eye Disease: A Randomized Controlled Study. (PubMed, Ophthalmol Ther) - P=N/A | "Both DQS and HA can improve the tear film of patients with diabetes and DED. DQS is more effective in treating DED compared to HA. Additionally, DQS may be beneficial for diabetic dry eye patients with corneal nerve damage."

Journal • Diabetes • Dry Eye Disease • Metabolic Disorders • Ophthalmology

Compare the Clinical Efficacy of 3% Diquafosol and 0.1% Hyaluronic Acid in Patients With Dry Eye After LASIK (clinicaltrials.gov) - P=N/A | N=140 | Not yet recruiting | Sponsor: He Eye Hospital

New trial • Dry Eye Disease • Ophthalmology

Diquafosol vs Hyaluronic Acid for Diabetic Dry Eye (clinicaltrials.gov) - P=N/A | N=99 | Completed | Sponsor: He Eye Hospital | Not yet recruiting ➔ Completed | N=202 ➔ 99

Enrollment change • Trial completion • Diabetes • Dry Eye Disease • Metabolic Disorders • Ophthalmology

Impact of 0.05% Cyclosporine A on Visual Quality in Patients with Post-refractive Surgery Dry Eye (ChiCTR) - P4 | N=52 | Recruiting | Sponsor: the Second Affiliated Hospital, School of Medicine, Zhejiang University; the Second Affiliated Hospital, School of Medicine, Zhejiang University

New P4 trial • Dry Eye Disease • Ophthalmology

A nationwide population-based study on epidemiologic characteristics and treatment patterns of dry eye disease in South Korea. (PubMed, Sci Rep) - "Single-use hyaluronic acid (HA) was most commonly prescribed (43.0%), followed by bottled steroids (24.5%), bottled HA (19.6%), and bottled diquafosol (4.3%). Annual prescriptions of cyclosporine and single-use steroids increased over time. Older patients were more likely to receive bottled formulations than single-use medication. This is the first nationwide study to examine DED prescription patterns on a large-scale population basis in South Korea, and the findings highlight the accessibility of HA-based therapies within a universal health coverage system, offering a distinct perspective compared to global patterns."

Journal • Dry Eye Disease • Ophthalmology

Topical Pharmacologic Treatments for Dry Eye Disease: A Systematic Review. (PubMed, Ocul Surf) - "Current topical pharmacologic eye products improved signs, and sometimes symptoms, of DED and were well tolerated. Treatment selection should use a shared decision-making approach that takes DED etiology and patient preferences into account."

Journal • Review • Dry Eye Disease • Inflammation • Ocular Inflammation • Ophthalmology

Comparison of the Therapeutic Effects of Rebamipide and Diquafosol on Apoptotic Damage of the Ocular Surface in Dry Eyes. (PubMed, Antioxidants (Basel)) - "DED was induced in vivo in C57BL/6 mice using subcutaneous scopolamine injection. Both treatments improved clinical outcomes in the murine dry eye model; however, REB showed superior efficacy in reducing ROS levels, lipid peroxidation, and apoptosis, and in preserving corneal glycocalyx integrity and conjunctival goblet cell density. These findings highlight the therapeutic potential and protective effects of REB against oxidative stress-related damage and apoptosis in DED."

Journal • Dry Eye Disease • Ocular Inflammation • Ophthalmology • CASP3 • CD4 • IFNG

Which topical ophthalmic drugs work best for Keratoconjunctivitis Sicca? A systematic review and meta-analysis. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "The study concluded that cyclosporine therapy offers improvements in corneal fluorescein staining but does not significantly affect other common DED symptoms, such as OSDI, TBUT, and Schirmer test scores. Similarly, no significant improvements in DED symptoms were observed with loteprednol etabonate or diquafosol sodium. Further research is needed to explore the efficacy of these treatments in managing DED symptoms more comprehensively."

Journal • Retrospective data • Conjunctivitis • Dry Eye Disease • Ocular Infections • Ocular Inflammation • Ophthalmology • Sjogren's Syndrome

Dry Eye Disease Management Via Technological Methods: A Systematic Review and Network Meta-analysis. (PubMed, Ophthalmol Ther) - "These findings underscore the potential of advanced technological interventions in the short-term management of DED and support the need for standardized, long-term comparative studies."

Journal • Retrospective data • Dry Eye Disease • Ophthalmology

Efficacy of 3% diquafosol sodium eye drops at different frequencies in the treatment of dry eye after FS-LASIK. (PubMed, Int J Ophthalmol) - "Within 1mo post-FS-LASIK, applying DQS six times daily is superior to four daily applications in improving CFS score, and in increasing NIBUT meanwhile. After 1mo, applying DQS four times daily also effectively alleviate DE symptoms and improve DE signs. Therefore, we recommend DE patients using DQS eye drops 6 times daily within 1mo after FS-LASIK, and maintaining it 4 times daily until 3mo postoperatively."

Journal • Dry Eye Disease • Ocular Inflammation • Ophthalmology

Uni-Bio Science Group Receives NMPA Approval for Diquafosol Sodium Eye Drops, Advancing Dry Eye Syndrome Treatment in China (The Manila Times) - "Uni-Bio Science Group Limited...proudly announces that its new ophthalmology product, Diquafosol Sodium Eye Drops, has received marketing approval from the China National Medical Products Administration (NMPA) [Approval Number: 國藥准字H20254149]."

China approval • Dry Eye Disease • Ophthalmology

Immune Checkpoint Inhibitor-Related Sjögren's Syndrome: An Ocular Immune-Related Adverse Event. (PubMed, Diagnostics (Basel)) - "A 67-year-old male with metastatic human papillomavirus (HPV)-positive oropharyngeal cancer receiving pembrolizumab (anti-programmed cell death protein 1 [PD-1] immune checkpoint inhibitor) presented with bilateral ocular dryness...Treatment with topical fluorometholone 0.1% and diquafosol 3% led to complete symptom resolution within one year while maintaining cancer immunotherapy. Long-term follow-up over 3.5 years demonstrated sustained ocular improvement and a favorable oncologic response without development of systemic autoimmune manifestations. This case highlights that Sjögren's syndrome as an irAE may present with isolated ocular manifestations, which could be overlooked in clinical practice."

Adverse events • Checkpoint inhibition • Journal • Conjunctivitis • Dry Eye Disease • Head and Neck Cancer • Immunology • Ocular Infections • Ocular Inflammation • Oncology • Ophthalmology • Oropharyngeal Cancer • Sjogren's Syndrome • Solid Tumor

Comparing Efficacy and Safety of TJO-083 in Dry Eye Diseases Patients (clinicaltrials.gov) - P3 | N=271 | Completed | Sponsor: Taejoon Pharmaceutical Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Mar 2025 ➔ Jul 2024 | Trial primary completion date: Dec 2024 ➔ May 2024

Trial completion • Trial completion date • Trial primary completion date • Dry Eye Disease • Ophthalmology

Characteristics of Patients with Dry Eye Who Switched from Long-Acting Ophthalmic Solution to Diquafosol Ophthalmic Solution. (PubMed, J Clin Med) - "An analysis of the group that preferred the DQS ophthalmic solution revealed no significant changes in subjective symptoms or fluorescein staining scores after DQS treatment. DQSLX improved the subjective symptoms and objective findings of patients with dry eye relative to DQS."

Journal • Dry Eye Disease • Ophthalmology

Analysis of the effect of 3 % diquafosole sodium eye drops on the improvement of symptoms and signs of dry eye in patients during the wearing period of OK glasses (ChiCTR) - P=N/A | N=80 | Completed | Sponsor: Chongqing Aier Children's Eye Hospital; Aier Eye Hospital Chongqing Children 's

New trial • Dry Eye Disease • Ophthalmology

3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis (clinicaltrials.gov) - P3 | N=94 | Not yet recruiting | Sponsor: The University of Hong Kong

New P3 trial • Conjunctivitis • Dry Eye Disease • Ocular Infections • Ocular Inflammation • Ophthalmology

Applications of Diquafosol Sodium in Ophthalmology: A Comprehensive Review of Therapeutic Utility. (PubMed, Life (Basel)) - "Future research should focus on optimising formulations, treatment duration, and exploring potential combination therapies to maximise therapeutic outcomes. By targeting underlying pathophysiological mechanisms, diquafosol represents a significant advancement in ocular surface management and a valuable addition to existing therapies."

Journal • Review • Cataract • Dry Eye Disease • Graft versus Host Disease • Immunology • Ophthalmology

Quantitative Analysis of Ocular Surface Tear Film Using a Tear Film Analyzer (ARVO 2025) - "Dry eye patients were receiving topical treatment with diquafosol sodium, rebamipide, or artificial tears.The results for HC, DWDE, and ADDE were as follows: LLT: [31.9 ± 14.3, 48.9 ± 7.9, 39.9 ± 8.6 (nm)], MALT: [1474.8 ± 248.5, 1824.3 ± 489.8, 1917.7 ± 635.4 (nm)]LMU: [13.5 ± 9.4, 30.5 ± 15.3, 17.3 ± 9.3 (nm/mm2)]...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Dry Eye Disease • Ophthalmology

Pre-clinical Evaluation of Ectoine-Based Binary Combinations in Alleviating Dry Eye (ARVO 2025) - "Our findings indicate that these formulations can significantly improve tear production, enhance tear film stability, and reduce damage to the corneal surface. These results suggest that ectoine-based eye drops, particularly those combined with Diquafosol and LNnT, may provide effective relief for individuals suffering from dry eye syndrome, offering a promising alternative to existing treatments."

Preclinical • Dry Eye Disease • Ophthalmology • KRT10

Evidence on the Use of Topical Ciclosporin for Ocular Surface Disease: A Systematic Review and Meta-Analysis. (PubMed, Clin Exp Ophthalmol) - "Topical CsA treatment effect on ocular surface symptoms and staining suggests that CsA may be superior to the vehicle, AT or other topical treatment alternatives for OSD."

Journal • Retrospective data • Dry Eye Disease • Ophthalmology

Compare the Clinical Efficacy of 3% Diquafosol and 0.1% Hyaluronic Acid in Patients with Dry Eye After Trans-PRK (clinicaltrials.gov) - P=N/A | N=76 | Not yet recruiting | Sponsor: He Eye Hospital

New trial • Dry Eye Disease • Ophthalmology

Temporal changes in parameters associated with tear film stability after instillation of long-acting diquafosol ophthalmic solution in soft contact lens wearers. (PubMed, Jpn J Ophthalmol) - "Compared to DQS, when wearing SCLs, DQS LX was found to increase the amount of tear fluid and improve tear film stability for longer periods."

Journal • Ophthalmology

Efficacy of 0.05% Cyclosporine-A eye drops (II) and 3% Diquafosol ophthalmic solution in the treatment of dry eye after cataract surgery. (PubMed, Pak J Med Sci) - "Patients were divided into three groups based on the treatment: Conventional group (tobramycin & dexamethasone eye drops combined with pranoprofen eye drops, n=41), DQS group (3% DQS based on the conventional treatment, n=42), and CsA group (0.05% CsA eye drops(II) based on the conventional treatment, n=40). However, these indexes were comparable in the DQS and the CsA group (P>0.05). Compared to the conventional treatment alone, the addition of 3% DQS or 0.05% CsA eye drops (II) to the conventional treatment both are effective and might more effectively alleviate DE in patients undergoing CS."

Journal • Surgery • Cataract • Dry Eye Disease • Ocular Inflammation • Ophthalmology

Glia-like taste cells mediate an intercellular mode of peripheral sweet adaptation. (PubMed, Cell) - "Aligning with our cellular-level findings, purinergic activation of type I cells attenuated sweet licking behavior, and P2RY2 knockout mice showed decelerated adaptation behavior. Our study highlights a veiled intercellular mode of sweet adaptation, potentially contributing to the efficient encoding of prolonged sweetness."

Journal